Pick the drugs you want to compare.
Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.
Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)
Side by side, line by line.
Compare across
11 dimensions
Opioid Agonist
Hydrocodone Bitartrate and Homatropine Methylbromide
Brand: Hycodan
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$1.24Per unit
$0.098Per unit
Average NADACAcross all dosage forms and strengths
$11.27Up to $36.36
$0.675Up to $0.964
Generic manufacturersActive ANDA holders — FDA Orange Book
530 total ANDAs filed
66 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$139.6MFull year
—Full year
Part D claims (CY24)Total fills, all strengths
1.2M205K beneficiaries
—— beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$115Per claim, all NDCs
—Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
1102Substantial friction
—Zero PA friction
Step therapy appliedPlan-NDC pairs requiring step therapy
5Limited friction
—None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
Active shortageSee drug profile
DiscontinuedSee drug profile
Generic availableFDA Orange Book
Yes5 manufacturers
Yes6 manufacturers